LEXX (Lexaria Bioscience Corp) Market Value to Book Value Ratio

Official company branding of lexariabioscience.com (LEXX)

The current market value of Lexaria Bioscience (LEXX) shown on this chart allows for an assessment of the efficiency of DehydraTECH, which minimizes losses by offering licenses for the transport of drugs for various diseases. The current indicator stands at 1.04. Returns are based on the implementation of innovations by partners, ensuring a moderate level of cash flows. Capitalization growth relies on the successful deployment of patented drug absorption software and strict monitoring of trial costs.

LEXX lexariabioscience.com: Market Value to Book Value in the range 07/04/2022 - 10/27/2026
Original product of lexariabioscience.com

For Lexaria Bioscience, a developer of scalable drug delivery systems, this indicator defines the gap between market expectations and actual assets. The metric compares the current share price with net assets, revealing a predominance of speculative demand over fundamentals. Analyzing the ratio of the company's market valuation to its book value allows for the timely detection of overheated quotes. This is critically important for a licensing business model, as the value of patents is often understated on the balance sheet. An investor must distinguish objective value growth from dangerous market optimism.

Main competitors

Market Cap to Net Assets Ratio Haleon plc|KVUE (kenvue.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Verona Pharma VRNA|Market Capitalization to Net Assets Jyong Biotech Limited|Ligand Pharma (LGND) - Market Capitalization to Book Value Ratio|Market Value to Book Value Amneal Corp (AMRX)|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|alvotech.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Liquidia (LQDA)|GLPG: Market Value to Book Value|ANIP (ANI Pharma) - Market Value to Book Value Ratio|Afrezza (MNKD) - Market Cap to Net Assets Ratio|AMPH (Amphastar Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pacira.com (PCRX)|ARS Pharmaceuticals, Inc. (SPRY) - Market Cap to Net Assets Ratio|Market Value to Book Value TBPH (Theravance Biopharma Inc)|AQST: Market Value to Book Value Ratio|SCPH - Market-to-Book Ratio|Market Cap to Net Assets Ratio Tectonic TECX|TNXP - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio sxtchina.com SXTC|Eupraxia Pharmaceuticals Inc. (EPRX) - Market Value to Book Value|Market Capitalization to Book Value Ratio BHST (BioHarvest)|Market-to-Book Ratio EXOZ|Oramed Pharmaceuticals (ORMP) - Market Value to Book Value Ratio|Market Value to Book Value ENTX (enterabio.com)|Market Value to Book Value Ratio MindWalk Holdings Inc. HYFT|Market Value to Book Value Ratio ABVC BioPharma Inc. ABVC|CPIX (Cumberland Pharma) - Market Capitalization to Book Value Ratio|Quantum BioPharma Corp (QNTM) - Market-to-Book Ratio|Market Cap to Net Assets Ratio FibroGen, Inc.|telomirpharma.com (TELO) - Capitalization to Book Value Ratio|RANI (Rani Therapeutics Holdings) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio SNYR|Rallybio Corporation (RLYB) - Market Value to Book Value Ratio|Market Value to Book Value Pulmatrix Corporation (PULM)|Market Capitalization to Book Value Ratio PTHL|Market Capitalization to Book Value Aptorum Group Ltd APM|Lyra Therapeutics - Market Capitalization to Book Value Ratio|impactbiomedinc.com (IBO) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio tnfpharma.com TNFA|cbdMD (YCBD) - Market Value to Book Value|Market Capitalization to Book Value Ratio PainReform Ltd.|Market Value to Book Value Ratio Auris Medical|LIPO (Lipella Pharmaceuticals, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value OPTN (OptiNose Inc)|PIRS: Market Value to Book Value Ratio|Procaps Group Corp - Market-to-Book Ratio|Market Value to Book Value Ratio PTPI (Petros Pharmaceuticals)|QLI - Market Capitalization to Book Value|SLRN (ACELYRIN) - Market Capitalization to Book Value Ratio|TFF Pharmaceuticals Inc. (TFFP) - Market Cap to Net Assets Ratio